An 83‐year‐old patient with RET fusion‐positive non‐small cell lung cancer experiencing severe hepatic disorder due to selpercatinib administration

An 83‐year‐old woman with RET fusion‐positive advanced lung adenocarcinoma was administered selpercatinib 320 mg/day. Despite the shrinking of the tumour, fever, fatigue, and anorexia developed on day 17. Selpercatinib administration was interrupted. On day 21, elevated blood aspartate aminotransfer...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakashima, Kazuhisa, Mitarai, Yuki, Tanaka, Seiko, Nakao, Mika, Okuno, Takae, Okimoto, Tamio, Tanabe, Ryo, Yanagawa, Takashi, Tsubata, Yukari, Isobe, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083545/
https://www.ncbi.nlm.nih.gov/pubmed/37051304
http://dx.doi.org/10.1002/rcr2.1136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083545/
https://www.ncbi.nlm.nih.gov/pubmed/37051304
http://dx.doi.org/10.1002/rcr2.1136

Ejemplares similares